{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:47:44Z","timestamp":1761486464270},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,7,26]],"date-time":"2001-07-26T00:00:00Z","timestamp":996105600000},"content-version":"vor","delay-in-days":206,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Donor lymphocyte transfusion has gained considerable interest as adoptive cellular immunotherapy for prevention or treatment of relapse after allogeneic stem cell transplantation. This study was designed to compare the yield of CD3<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>4<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>8<jats:sup>+<\/jats:sup>, CD19<jats:sup>+<\/jats:sup>, CD3<jats:sup>\u2212<\/jats:sup>56<jats:sup>+<\/jats:sup>16<jats:sup>+<\/jats:sup>, and CD34<jats:sup>+<\/jats:sup> cells contained in apheresis products from 61 consecutive non\u2010cytokine treated, human leukocyte antigen (HLA)\u2010matched donors for lymphocyte collection with the corresponding apheresis\u2010derived cell yield from 112 consecutive, HLA\u2010matched donors for blood stem cell collection who received recombinant human granulocyte colony stimulating factor (rhG\u2010CSF, filgrastim) 6 \u03bcg\/kg every 12 hours until cell collection was completed. Apheresis was started on day 4 or 5 of rhG\u2010CSF treatment. The yield of lymphoid subsets was significantly different in the two sample groups, rhG\u2010CSF treated product yields exceeding untreated product yields by a median of 2.1\u2010fold (range: 1.3\u20132.6). However, the CD34<jats:sup>+<\/jats:sup> cell yield in rhG\u2010CSF\u2010treated apheresis products exceeded untreated products by 26\u2010fold. A single untreated apheresis procedure was usually sufficient to collect a target dose of 1 \u00d7 10<jats:sup>8<\/jats:sup>\/kg CD3<jats:sup>+<\/jats:sup> cells. Untreated apheresis products contained a median of 0.2 \u00d7 10<jats:sup>6<\/jats:sup>\/kg CD34<jats:sup>+<\/jats:sup> cells. A potential engraftment dose of \u22650.5 \u00d7 10<jats:sup>6<\/jats:sup> CD34<jats:sup>+<\/jats:sup> cells per kg of recipient body weight was contained in 16% of 57 untreated apheresis products. One single apheresis performed in a normal, untreated donor provides a sufficient amount of CD3<jats:sup>+<\/jats:sup> cells for adoptive immunotherapy. Compared with that of an rhG\u2010CSF stimulated apheresis product, the CD34<jats:sup>+<\/jats:sup> cell count is usually, but not always, below the engraftment dose range. RhG\u2010CSF treatment has little effect on the yield of lymphoid subsets collected by apheresis but is highly selective of the release of CD34<jats:sup>+<\/jats:sup> cells. This report provides baseline data for studies that will show whether other cytokines such as granulocyte macrophage colony stimulating factor (GM\u2010CSF) and\/or Flt\u20103 Ligand can immunomodulate allotransfusates in vivo to improve the graft\u2010vs.\u2010leukemia (GVL) effect after allogeneic stem cell transplantation, while lowering the incidence and severity of graft\u2010vs.\u2010host disease (GVHD). J. Clin. Apheresis. 16:82\u201387, 2001. \u00a9 2001 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jca.1017","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:50:10Z","timestamp":1030305010000},"page":"82-87","source":"Crossref","is-referenced-by-count":9,"title":["Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis"],"prefix":"10.1002","volume":"16","author":[{"given":"M.","family":"K\u00f6rbling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Anderlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"McMannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,7,26]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2462.2462"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.5.1379.1379"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2273.2273"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90624-6"},{"key":"e_1_2_1_6_2","first-page":"109","article-title":"Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following BMT","volume":"11","author":"Szer J","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195"},{"key":"e_1_2_1_8_2","first-page":"643","article-title":"Intensive chemotherapy followed by donor PBSC in ANNL relapsed after allogeneic BMT","volume":"15","author":"Bernasconi P","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_9_2","first-page":"669","article-title":"Graft\u2010versus\u2010leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon G","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90871-5"},{"key":"e_1_2_1_12_2","first-page":"563a","article-title":"Donor leukocyte infusion for post\u2010bone marrow transplant relapse: retrospective cohort analysis of 141 cases","volume":"86","author":"Collins R","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404283301703"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331603"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198903303201303"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701131"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1996.36796323057.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"e_1_2_1_21_2","first-page":"53","article-title":"Bone marrow transplantation for chronic myeloid leukaemia: T\u2010cell depletion with Campath\u20101 reduces the incidence of acute graft\u2010versus\u2010host disease but may increase the risk of leukaemic relapse","volume":"1","author":"Apperley JF","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood.V83.11.3409.3409","article-title":"Minimal residual disease is more common in patients who have mixed T\u2010cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia","volume":"83","author":"Mackinnon S","year":"1994","journal-title":"Blood"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40040393.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40040468.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1182\/blood.V86.7.2842.2842","article-title":"Allogeneic blood stem cell transplantation: peripheralization and yield of donor\u2010derived primitive hematopoietic progenitor cells (CD34+ Thy\u20101 dim) and lymphoid subsets, and possible predictors of engraftment and graft\u2010versus\u2010host disease","volume":"86","author":"Korbling M","year":"1995","journal-title":"Blood"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.4.1465.416k12_1465_1470"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.12.4422.bloodjournal86124422"},{"key":"e_1_2_1_28_2","first-page":"722a","volume":"92","author":"Tarantolo SR","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood.V89.9.3113","article-title":"Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia","volume":"89","author":"Keil F","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4337.bloodjournal86114337"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5319.1719"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.1017","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.1017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T17:03:38Z","timestamp":1700413418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.1017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1002\/jca.1017"],"URL":"https:\/\/doi.org\/10.1002\/jca.1017","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}